Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$0.78
+1.4%
$0.69
$0.45
$1.99
$58.55M1.43401,318 shs110,293 shs
Mallinckrodt plc stock logo
MNK
Mallinckrodt
$0.34
$0.75
$6.42
$1.58MN/A2.62 million shs39,227 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$0.34
-0.3%
$0.35
$0.26
$2.83
$42.75M0.792.77 million shs1.33 million shs
Merus N.V. stock logo
MRUS
Merus
$55.62
+2.1%
$50.76
$33.19
$62.98
$3.85B1732,623 shs694,277 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.49
+4.4%
$3.51
$2.28
$6.71
$569.56M1.71.14 million shs678,167 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
0.00%+11.34%+27.24%-3.16%-18.53%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00%0.00%0.00%0.00%0.00%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%+18.59%-6.35%+3.77%-83.47%
Merus N.V. stock logo
MRUS
Merus
0.00%+1.23%-0.20%+28.45%-4.82%
Organogenesis stock logo
ORGO
Organogenesis
0.00%-1.15%+40.07%-0.69%+47.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
4.0696 of 5 stars
3.52.00.04.72.70.80.6
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
4.2015 of 5 stars
3.53.00.04.12.72.50.0
Merus N.V. stock logo
MRUS
Merus
1.9195 of 5 stars
3.61.00.00.02.02.50.0
Organogenesis stock logo
ORGO
Organogenesis
4.413 of 5 stars
3.03.00.04.32.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.00
Buy$3.00286.10% Upside
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00
N/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.00
Buy$5.201,416.03% Upside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6452.17% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0033.63% Upside

Current Analyst Ratings Breakdown

Latest ORGO, MNK, CUE, MRSN, and MRUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$3.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/6/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$4.00 ➝ $3.00
4/28/2025
Merus N.V. stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$9.29M6.30N/AN/A$0.28 per share2.78
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A$47.48 per shareN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$40.50M1.06N/AN/A($0.08) per share-4.29
Merus N.V. stock logo
MRUS
Merus
$36.13M106.54N/AN/A$9.46 per share5.88
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.18$0.22 per share20.61$2.09 per share2.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)

Latest ORGO, MNK, CUE, MRSN, and MRUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/12/2025Q1 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.03
1.03
Mallinckrodt plc stock logo
MNK
Mallinckrodt
1.18
0.57
0.31
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.83
1.83
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67

Institutional Ownership

CompanyInstitutional Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
83.74%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
Merus N.V. stock logo
MRUS
Merus
96.14%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
12.26%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.30%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
13.00%
Merus N.V. stock logo
MRUS
Merus
4.57%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
6075.35 million66.11 millionOptionable
Mallinckrodt plc stock logo
MNK
Mallinckrodt
2,70013.17 million13.13 millionNot Optionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
150124.63 million108.43 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable

Recent News About These Companies

Organogenesis Holdings Inc. (ORGO) - Yahoo Finance
CMS reviewing coverage policies for skin substitute products

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$0.78 +0.01 (+1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$0.77 -0.01 (-1.42%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Mallinckrodt stock logo

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

$0.34 0.00 (-0.26%)
Closing price 04:00 PM Eastern
Extended Trading
$0.34 0.00 (0.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Merus stock logo

Merus NASDAQ:MRUS

$55.62 +1.12 (+2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$55.66 +0.04 (+0.07%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.49 +0.19 (+4.42%)
Closing price 04:00 PM Eastern
Extended Trading
$3.16 -1.34 (-29.73%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.